Quantcast

Latest Atherosclerosis Stories

2014-10-13 12:26:51

LA JOLLA, Calif., Oct. 13, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have created a synthetic molecule that mimics "good" cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks. This research, published in the October issue of Journal of Lipid Research, points scientists toward a new method for treating atherosclerosis, a condition where...

2014-09-29 08:32:29

TEL-AVIV, Israel, Sept. 29, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT(TM) devices and accessories from Itamar Medical Ltd. (TASE: ITMR) ("Itamar Medical"), a publicly-traded medical device company whose technology has...

2014-09-15 23:00:29

Imaging can be a cost-effective way to identify people at risk for stroke who might benefit from aggressive intervention, according to a new modeling study published online, September 16, in the journal Radiology. OAK BROOK, Ill. (PRWEB) September 15, 2014 Imaging can be a cost-effective way to identify people at risk for stroke who might benefit from aggressive intervention, according to a new modeling study published online in the journal Radiology. The study looked at people with...

2014-09-10 23:14:14

NuvOx Pharma has been awarded a Phase I Small Business Innovative Research contract (contract # HHSN268201400045C) for “Development of Molecular Imaging Agents and Methods to Detect High Risk Atherosclerotic Plaque” by the National Heart, Lung, and Blood Institute (NHLBI). Tucson, Arizona (PRWEB) September 10, 2014 Evan Unger, MD, President and CEO of NuvOx Pharma announced today that NuvOx Pharma has been awarded a Phase I Small Business Innovative Research contract (contract #...

2014-09-02 08:30:49

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: 'Effects of...

2014-09-01 16:22:55

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary...

2014-07-31 17:18:15

World Heart Federation Examining the remarkably preserved mummies of five ancient cultures, the Horus mummy research team discovered atherosclerosis (narrowing of the arteries due to build up of fatty deposits) was present in humans long before we acquired modern lifestyles. In a paper published in this month's edition of Global Heart (the journal of the World Heart Federation) the Horus team describes potential causes that could have led to atherosclerosis in ancient times, the...

2014-07-30 10:26:33

University of Texas Health Science Center at Houston Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation. At The University of Texas Health Science Center at Houston (UTHealth) Medical School, scientists tested a non-surgical preventative treatment in a mouse model of the...

2014-07-30 08:32:08

Anticipate Topline Data in 6-8 months IRVINE, Calif., July 30, 2014 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001...

2014-07-23 08:32:18

In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. TSX Exchange Symbol: RVX CALGARY, July 23, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in patients with diabetes mellitus (DM) enrolled in both the ASSURE and SUSTAIN trials. In ASSURE, MACE was a pre-specified...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.